ArticleVaccines2024

Long-Term Safety and Immunogenicity of AZD1222 (ChAdOx1 nCoV-19): 2-Year Follow-Up from a Phase 3 Study.

Kathryn Shoemaker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.